Biotech Holdings Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Holdings

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike Heimbuch who wrote (84)	12/9/1997 6:35:00 PM
From: tommysdad	Read Replies (1) of 224

You asked the question on the AMLN thread but here's the response: From a "scientific type" there is nothing to evaluate at this point. The following questions have no answers as yet from the company: 1) What is the structure of Diab II? 2) What is the patent position? When will the patent issue? 3) Where is some animal data in a peer-reviewed journal, in an accepted model for Type II diabetes? 4) What is the proposed mechanism of action? Are there data to support this proposal? 5) When will clinical trials start in a non-third world country? 6) What is Diab II marketed as in China? What were 3Q97 sales (in any currency)? The tone of this message is not to be harsh. It's just that I have looked at this company off and on for about nine months and solid, concrete, independently verifiable data is lacking (or hiding in places I cannot find), and it's a bit frustrating. Inquiries to the company produce annual reports and investor packets. I guess I should call again and try to talk to a human directly. At this point, to the North American scientific community, Diab II is a vapor product as far as I can tell. A link or a reference to prove me wrong would be most welcome. Good luck. Hope this works out for you.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next